Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring by Zhu, Jiangjiang et al.
  
1 
 
Analytical and Bioanalytical Chemistry 1 
 2 
Electronic Supplementary Material 3 
 4 
 5 
Targeted serum metabolite profiling and sequential metabolite ratio analysis 6 
for colorectal cancer progression monitoring 7 
 8 
Jiangjiang Zhu, Danijel Djukovic, Lingli Deng, Haiwei Gu, Farhan Himmati,  9 
Mohammad Abu Zaid, Elena Gabriela Chiorean and Daniel Raftery 10 
 11 
 12 
13 
  
2 
 
Supplemental Materials and Methods: 14 
Chemicals and reagents: LC-MS grade acetonitrile, ammonium acetate, and acetic acid were 15 
purchased from Fisher Scientific (Pittsburgh, PA). Standard compounds corresponding to the 16 
measured metabolites were purchased from Sigma-Aldrich (Saint Louis, MO) or Fisher 17 
Scientific (Pittsburgh, PA), and a list of these compounds can be found in the Supplementary 18 
Table S1. Stable isotope-labeled tyrosine and lactate (L-tyrosine-13C2 and sodium-L-lactate-13C3) 19 
were purchased from Cambridge Isotope Laboratories, Inc. (Tewksbury, MA). The purities of 20 
non-labeled standards were >95-99%, whereas the purities of the two 13C labeled compounds 21 
were >99%.    22 
Sample preparation: Frozen samples were first thawed at room temperature for approximately 23 
45 min, and 50 µL of each sample was protein precipitated using two rounds of cold methanol 24 
extraction (150 µL and 300 µL, respectively) at -20 °C. The resulting supernatant containing 25 
desired metabolites was collected into a new Eppendorf vial, dried using a Vacufuge Plus 26 
evaporator (Eppendorf, Hauppauge, NY), and then reconstituted in a 500 µL solution (40% 27 
water / 60% acetonitrile with 5 mM ammonium acetate and 0.2% acetic acid) containing 5.13 28 
µM L-tyrosine-13C2 and 22.5 µM sodium-L-lactate-13C3. The two isotope-labeled internal 29 
standards were added to monitor system performance. The samples were filtered through 0.45 30 
µm PVDF filters (Phenomenex, Torrance, CA) prior to LC-MS analysis. A pooled human serum 31 
sample was extracted using the same procedure as above. This sample was used as the quality 32 
control (QC) sample and was analyzed once every ten serum samples. All patient samples were 33 
randomized before LC-MS analysis. 34 
LC-MS/MS system and conditions: The LC system consisted of two Agilent 1260 binary 35 
pumps, an Agilent 1260 auto-sampler, and an Agilent 1290 column compartment containing a 36 
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column-switching valve (Agilent Technologies, Santa Clara, CA). Two separate injections (10 37 
µL for analysis using negative ionization mode and 2 µL for analysis using positive ionization 38 
mode) were made for each sample. Chromatographic separations were performed using 39 
hydrophilic interaction chromatography (HILIC) on two SeQuant ZIC-cHILIC columns (150 x 40 
2.1 mm, 3.0 µm particle size, Merck KGaA, Darmstadt, Germany) connected in parallel. This 41 
setup facilitates high-throughput analysis as it allows one column to perform the separation while 42 
the other column is being reconditioned for the next sample injection. The reconstituted serum 43 
samples were gradient-eluted at 0.300 mL/min using solvents A (5 mM ammonium acetate in 44 
90% water / 10% acetonitrile + 0.2% acetic acid) and B (5 mM ammonium acetate in 90% 45 
acetonitrile / 10% water + 0.2% acetic acid). The auto-sampler temperature was kept at 4 °C, the 46 
column compartment was set at 40 °C, and the separation time for each ionization mode was 20 47 
min. The gradient conditions for both separations were identical and are briefly summarized as 48 
follows: 75% B isocratic for 2 min, 75% B to 30% B in 3 min, 30% B isocratic for 4 min, back 49 
to 75% B in 2 min, and then remaining at 75% B for 9 min.  50 
The metabolite identities were confirmed by spiking the pooled serum sample used for 51 
method development with mixtures of standard compounds (each mixture contained five 52 
standard metabolites). The few metabolites that could not be well separated and had similar m/z 53 
values (<1 Da) were integrated as single peaks (e.g., malonic acid and 3-hydroxybutyric acid). 54 
The mass spectrometer setting was optimized and described as follows. Briefly, after the 55 
chromatographic separation, MS ionization and data acquisition were performed using an AB 56 
Sciex QTrap 5500 mass spectrometer (AB Sciex, Toronto, ON, Canada) equipped with an 57 
electrospray ionization (ESI) source. The instrument was controlled by Analyst 1.5 software (AB 58 
Sciex). Targeted data acquisition was performed in multiple-reaction-monitoring (MRM) mode. 59 
  
4 
 
We monitored 105 and 57 MRM transitions in negative and positive mode, respectively (162 60 
transitions in total). The source and collision gas was N2 (99.999% purity). The ion source 61 
conditions in negative/positive mode were as follows: curtain gas (CUR) = 25 psi, collision gas 62 
(CAD) = high, ion spray voltage (IS) = -3.8/3.8 KV, temperature (TEM) = 500 °C, ion source 63 
gas 1 (GS1) = 50 psi, and ion source gas 2 (GS2) = 40 psi. The optimized MS conditions for 64 
each compound were optimized with chemical standards.  65 
  66 
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Supplemental data: 67 
Table S1 List of targeted metabolites in this study (verified by chemical standards)  68 
Glycine  Normetanephrin  Ribose-5-P  
Trimethylamine-N-oxide  Histamine  Adenylosuccinate  
Alanine  Pyruvate  D-Leucic acid  
Aminoisobutyrate  Lactate  GDP  
Choline  Acetoacetate  GTP  
Dimethylglycine  Fumaric  DCDP  
Serine  Succinate  Pyridoxal-5-P  
Creatinine  Nicotinate   Gibberellin  
Proline  Glutaric acid  Adipic acid  
Valine  Malate  Maleic acid  
Betaine  Hypoxanthine  Methylmalonate  
Threonine  alpha-Ketoglutaric acid  DHAP  
Taurine  Xanthine  Chenodeoxycholate  
Creatine  PPA  G16BP  
Hydroxyproline  Urate  F6P/F1P  
Leucine/iso-Leucine  Homogentisate  Oxalic acid  
Ornithine  PEP  Glyceraldehyde  
Homocysteine  D-GA3P  Glycerate  
Acetylcholine  Glycerol-3-P  N-Acetylglycine  
Glutamine  Hyppuric acid  Guanidinoacetate  
Glutamic acid  Glucose  Mevalonate  
Methionine  4-Pyridoxic acid  Allantoin  
Cystamine  2/3-Phosphoglyceric acid  Inositol  
Histidine  Erythrose  Homovanilate  
Carnitine  Cystathionine  Xanthurenate  
Phenylalanine  G1P/G6P  Pentothenate  
Arginine  Reduced glutatione  Biotin  
Glucosamine  F16BP/F26BP  DCMP  
Tyrosine  Sucrose  DUMP  
Sorbitol  5-Formyl THF   Geranyl pyrophosphate  
Epinephrine  Oxidized glutathione  DTMP  
Tryptophan  gamma-Aminobutyrate  CMP  
5-Hydroxytryptophan  Malonic acid/3HBA  Lactose  
Uridine  Citraconic acid  cGMP  
Phosphotyrosine  Adenine  AMP  
Adenosine  Shikimic acid  IMP  
Inosine  Aconitate  PGE  
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Guanosine  Citrulline  OMP  
XMP  Citric acid  UDP  
L-Kinurenine  Cystine  ADP  
Lysine  Xanthosine  Folic acid  
Cytosine  Uracil  DUTP  
Homoserine  OH-Phenylpyruvate  ATP  
Niacinamide  Glycochenodeoxycholate  Taurocholate  
1-Methylhistamine  Glycocholate  Fructose  
Asparagine  Dopamine  Aspartic acid  
Salicylurate  Melatonin  Methylsuccinate  
2'-Deoxyuridine  Orotate  Myristic acid  
3-Hydroxykynurenine  Anthranilate  Margaric acid  
Cytidine  Glucoronate  Linoleic acid  
Pyroglutamic acid  Oxaloacetate  Linolenic acid  
1-Methyladenosine  Propionate  Galactose  
1-Methylguanosine  2-Aminoadipate    
N2,N2-Dimethylguanosine  Kynorenate    
Aminolevulinic acid  3-Nitro-tyrosine    
 69 
  70 
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Table S2 Detailed patient and sample information 71 
 72 
a
 BMI information was not obtained for five patients. 73 
b
 Disease status: DP, Disease Progression; AD, At Diagnosis; SD, Stable Disease; CR, Complete 74 
Remission; RD, Recurrent Disease; TR, Tumor Response; LM, Liver Metastasis. There were 75 
only three groups of disease status (CR, DP and SD) remaining after the ratio calculation. 76 
  77 
Patient  Gender Age at  Consent BMI
a
 Diagnosis Stage # of blood draws 
Disease Status b 
(follow the blood 
draw order) 
1 M 29 30.4 Colon Cancer Stage IV 4 DP, SD, DP, DP 
2 M 32 28.1 Colon Cancer Stage III 2 DP, DP 
3 M 37 - Colon Cancer Stage IV 2 DP, DP 
4 F 42 18.9 Colon Cancer Stage IV 3 RD, DP, SD 
5 F 42 - Colon Cancer Stage I/II 2 AD, CR 
6 F 45 28.1 Colon Cancer Stage IV 2 DP, DP 
7 F 45 20.4 Colon Cancer Stage IV 3 DP, DP, DP 
8 F 46 27.5 Rectal Cancer Stage IV 2 TR, CR 
9 F 50 22.7 Colon Cancer Stage IV 2 DP, DP 
10 M 51 29.0 Colon Cancer Stage III 2 AD, CR 
11 F 55 25.6 Colon Cancer Stage IV 4 LM, CR, CR, CR 
12 M 55 - Colon Cancer Stage IV 2 DP, SD 
13 M 65 24.4 Rectal Cancer Stage III 2 CR, CR 
14 F 66 - Colon Cancer Stage I/II 3 AD, CR, CR 
15 F 66 24.0 Colon Cancer Stage IV 3 DP, SD, DP 
16 F 68 22.3 Rectal Cancer Stage IV 3 DP, SD, DP 
17 M 68 27.6 Colon Cancer Stage IV 2 SD, SD 
18 M 73 - Colon Cancer Stage IV 2 SD, SD 
19 M 77 32.2 Colon Cancer Stage III 2 SD, SD 
20 F 86 25.4 Colon Cancer Stage IV 2 DP, DP 
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Table S3 Summary of metabolites with high VIP scores (VIP>1.5) using sequential metabolite 78 
ratios in comparing DP vs. CR + SD 79 
Metabolite VIP FC* FDR 
N2,N2-Dimethylguanosine  2.15 1.34 0.18 
Citraconic Acid  2.04 1.58 0.29 
1-Methylguanosine  2.04 1.25 0.29 
Succinate  2.01 1.33 0.23 
Adenine  2.01 1.11 0.37 
Methylmalonate 1.84 1.31 0.31 
3-Nitro-tyrosine  1.83 0.84 0.20 
Malonic Acid/3HBA  1.77 5.99 0.14 
G16BP 1.76 1.05 0.17 
Urate  1.76 1.15 0.33 
Aconitate  1.73 1.45 0.31 
Homogentisate  1.66 1.19 0.14 
Methylsuccinate  1.61 0.80 0.41 
1-Methyladenosine  1.61 1.15 0.17 
Cystathionine  1.60 0.65 0.20 
Linolenic Acid  1.58 1.77 0.40 
Cytidine  1.57 1.39 0.36 
Pyruvate  1.57 0.64 0.33 
Alanine  1.55 0.80 0.25 
gamma-Aminobutyrate  1.53 0.82 0.44 
*Fold change represents the average metabolite ratio for disease 80 
progression samples compared to samples from complete remission 81 
and stable disease. 82 
 83 
  84 
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Table S4 Summary of PLS-DA model performance using different numbers of sequential 85 
metabolite ratios for the differentiation of DP vs. CR + SD 86 
 87 
a See Table S3 for metabolites and their corresponding VIP scores 88 
 89 
 90 
 91 
Table S5 Summary of metabolites with p-value <0.05 using sequential metabolite ratios in 92 
comparing DP vs. CR + SD in stage IV patients 93 
Metabolites p-value  FC* FDR 
1-Methylguanosine 7.1E-03 1.27 0.18 
N2,N2-Dimethylguanosine 1.3E-02 1.33 0.18 
Adenine 1.5E-02 1.12 0.31 
Succinate 1.8E-02 1.33 0.25 
Pyruvate 3.0E-02 0.62 0.27 
Methylmalonate 3.0E-02 1.28 0.25 
Homogentisate 3.0E-02 1.22 0.14 
Urate 3.0E-02 1.18 0.25 
Citraconic Acid 4.9E-02 1.47 0.25 
 94 
*Fold change represents the average metabolite ratio for disease progression samples compared 95 
to samples from other groups. 96 
 97 
  98 
PLS-DA Models 
Metabolites 
selection 
Threshold 
# of Metabolites 
used in the 
modela 
AUROC Sensitivity Specificity 
DP vs. CR+SD        
(Metabolites only 
models) 
VIP>1.5 20 0.92 0.92 0.88 
VIP>1.8 7 0.90 0.83 0.94 
VIP>2 5 0.91 0.83 0.94 
DP vs. CR+SD       
(Metabolites + CEA 
models) 
VIP>1.5 20 0.92 0.92 0.88 
VIP>1.8 7 0.89 0.83 0.94 
VIP>2 5 0.91 0.83 0.94 
  
99 
Fig. S1 Individual ROC curves for the top six metabolites with 100 
CR and SD using sequential metabolite ratios101 
dimethylguanosine, AUROC=0.82; (C) citraconic acid, AUROC=0.81; (D) adenine, 102 
AUROC=0.81; (E) methylmalonate, AUROC=0.81; and (F) 1103 
 104 
 105 
 106 
 107 
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p-value<0.01 comparing 
: (A) succinate, AUROC=0.83; (B) N2,N2
-methylguanosine, 
 
DP with 
-
AUROC=0.79 
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Figure S2 (A)ROC of PLS-DA model using five metabolites (with VIP>2) and CEA ratios for 111 
DP vs. CR + SD: AUROC= 0.912 (increased from 0.907, see Figure S3); sensitivity= 0.83; 112 
specificity= 0.94, FDR=0.09. (B) Monte Carlo cross validation (MCCV)113 
the same metabolites: True, true class models; Random, random permutation model. The testing 114 
specificities were 0.95, 0.85, and 0.75. Error bars showing the standard deviati115 
MCCV results 116 
 117 
 118 
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Fig. S3 ROC of PLS-DA mod120 
CR + SD in stage IV patients: AUROC= 0.84, sensitivity= 0.91,121 
122 
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Fig. S4 A metabolome view showing all impacted metabolic pathways in this study analyzed 128 
using MetaboAnalyst(2.0), and using both scores from enrichment analysis (y axis) and from 129 
topology analysis (x axis). Due to space restriction only 130 
0.3 are labeled 131 
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